Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
26 nov. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI...
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
12 nov. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London...
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
29 oct. 2024 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $410 - $420 million –– Life...
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
28 oct. 2024 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care – LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals...
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
22 oct. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024...
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
01 oct. 2024 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, has teamed up with National Hockey...
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
28 août 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo...
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
23 juil. 2024 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $405 - $415 million...
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
16 juil. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at...
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
09 juil. 2024 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Abiprubart Phase 2b clinical trial in Sjögren’s Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – – Abiprubart clinical development in Sjögren’s...